AbbVie and Sosei agreed to cooperate in the field of drug development

Company AbbVie and Sosei concluded an agreement on joint development of drugs, the cost of which may reach $ 1 billion, writes Reuters.

The parties will work together to conduct research and commercialize drugs specific to the receptors associated with G-protein (GPCR). As a down payment to Sosei will receive $ 32 million, together with subsequent payments and royalties from sales total amount of payments could reach $ 1 billion. AbbVie will also have the opportunity to expand cooperation and development of the four candidate drugs.

The development of similar drugs with Sosei cooperate with Genentech, and Takeda.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]